Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (16940)	5/27/2005 8:18:47 AM
From: gcrispin	Read Replies (2) \| Respond to of 52153

The EYET CC certainly suggests that PDT isn't dead, and that combination therapy will be the predominant treatment. There probably should be a link on the QLT website to the conference call. I am looking forward to all the studies that will be presented this year. One item of note from the conference call. All companies will be looking for a way to diminish the frequency of injections and extend the duration between VEGF treatments. Guyer mentioned trials this year using a microsphere delivery system and QLT has stated they will begin trials next year using Atrigel, though they have not identified a partner.